Acquired Company
Acelyrin completed its merger with Alumis on 5/21/2025.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company is headquartered in Agoura Hills, California. Show more
4149 LIBERTY CANYON ROAD, AGOURA HILLS, CA, UNITED STATES, 91301, Agoura Hills, CA, 91301, USA
Market Cap
229.2M
52 Wk Range
$0.00 - $0.00
Previous Close
$2.27
Open
$2.27
Volume
N/A
Day Range
$2.27 - $2.27
Enterprise Value
-174.4M
Cash
58.27M
Avg Qtr Burn
-38.96M
Insider Ownership
7.15%
Institutional Own.
91.98%
Qtr Updated
03/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Lonigutamab Details Thyroid Eye Disease , Eye disease | Phase 3 Initiation | |
Izokibep Details Axial spondyloarthritis | Failed Discontinued | |
Izokibep Details Psoriatic arthritis | Failed Discontinued | |
SLRN-517 Details Allergy, Inflammatory disease, KIT/Mast cell diseases | Failed Discontinued | |
Izokibep Details Hidradenitis suppurativa | Failed Discontinued | |
Izokibep Details Uveitis , Eye disease | Failed Discontinued |
